What is the PE ratio of Madrigal?
Madrigal Pharmaceuticals, Inc. (MDGL) trades with a negative price-to-earnings ratio of approximately -36.3, which is standard for commercial-stage biotechnology enterprises heavily reinvesting capital into drug commercialization, market access, and ongoing clinical research pipelines. Rather than relying on traditional P/E multiples, equity analysts evaluate the company's valuation based on projected sales trajectory, commercial adoption rates for its breakthrough nonalcoholic steatohepatitis treatments, and peak revenue potential.
Related FAQs
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. officially became a publicly traded biopharmaceutical company through a strategic reverse merger and corporate restructuring completed in July 2016.
As of July 30, 2026, market analysts and forecasting platforms anticipate that Madrigal Pharmaceuticals (MDGL) stock will operate within a trading channel ranging from $547.20 to $1,119.46 throughout the 2026 fiscal year.
Madrigal Pharmaceuticals (MDGL) is widely evaluated by biotechnology sector specialists as an attractive buy opportunity, supported by consensus analyst ratings heavily skewed toward buy and strong buy recommendations.
Madrigal Pharmaceuticals (MDGL) is predominantly rated as a buy by institutional equity research analysts tracking the biopharmaceutical sector.
Madrigal Pharmaceuticals (MDGL) presents a compelling profile for long-term investors seeking exposure to specialized pharmaceutical innovation, primarily due to its breakthrough positioning in treating chronic metabolic liver diseases like MASH.
Madrigal Pharmaceuticals functions primarily as a commercial-stage biopharmaceutical enterprise that has historically incurred substantial research, development, and commercialization expenses characteristic of innovative drug developers scaling up p...
Analyzing the stock volatility of MDA Ltd.—a leading space technology, satellite systems, and geointelligence enterprise based in Canada—reveals a moderate to high volatility profile.
Evaluating Madrigal Pharmaceuticals as a potential equity investment requires weighing its pioneering position in commercializing breakthrough treatments for nonalcoholic steatohepatitis against the high clinical development risks and regulatory hurd...
Madrigal Pharmaceuticals, Inc. is a clinical-stage and commercial biopharmaceutical enterprise that sells innovative specialty therapeutics targeting metabolic dysfunction-associated steatohepatitis.
MDGL is the stock ticker symbol for Madrigal Pharmaceuticals, Inc., a publicly traded biopharmaceutical company listed on the Nasdaq.
Madrigal Pharmaceuticals, Inc.
Financial analysts following Amneal Pharmaceuticals often highlight its growth potential driven by a expanding pipeline of complex generics and high-value specialty products.
No, Main Street Capital Corporation has never cut its regular monthly or quarterly dividend payouts to shareholders since its initial public offering.
Madrigal Pharmaceuticals focuses on developing and commercializing innovative therapeutic treatments for metabolic and liver-related diseases, with its premier flagship drug being Rezdiffra, chemically known as resmetirom.
The share price of Madrigal Pharmaceuticals, Inc. (traded on the NASDAQ Global Select Market under the ticker MDGL) is approximately 482.00 USD.
Madrigal Pharmaceuticals, Inc. is principally located in West Conshohocken, Pennsylvania, United States.